These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 22316275

  • 1. Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
    Delea TE, Rotter J, Taylor M, Chandiwana D, Bains M, El Ouagari K, Kaura S, Morgan GJ.
    J Med Econ; 2012; 15(3):454-64. PubMed ID: 22316275
    [Abstract] [Full Text] [Related]

  • 2. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.
    J Med Econ; 2018 May; 21(5):525-536. PubMed ID: 29480139
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma.
    Delea TE, El Ouagari K, Rotter J, Wang A, Kaura S, Morgan GJ.
    Curr Oncol; 2012 Dec; 19(6):e392-403. PubMed ID: 23300363
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S.
    Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
    [Abstract] [Full Text] [Related]

  • 5. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Studies Group.
    Blood; 2012 Jun 07; 119(23):5374-83. PubMed ID: 22498739
    [Abstract] [Full Text] [Related]

  • 6. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L.
    Health Technol Assess; 2016 Jul 07; 20(53):1-288. PubMed ID: 27434595
    [Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.
    Br J Haematol; 2014 Jul 07; 166(1):109-17. PubMed ID: 24673708
    [Abstract] [Full Text] [Related]

  • 8. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE, National Cancer Research Institute Haematological Oncology Clinical Studies Group.
    Lancet Oncol; 2011 Aug 07; 12(8):743-52. PubMed ID: 21771568
    [Abstract] [Full Text] [Related]

  • 9. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA, National Cancer Research Institute Haematological Oncology Clinical Study Group.
    Lancet; 2010 Dec 11; 376(9757):1989-99. PubMed ID: 21131037
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct 11; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012 Oct 11; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

  • 13. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 Oct 11; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 14. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    J Med Econ; 2013 Oct 11; 16(1):19-29. PubMed ID: 22870908
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands.
    Carter JA, Joshi A, Kaura S, Botteman MF.
    J Med Econ; 2011 Oct 11; 14(3):288-98. PubMed ID: 21469915
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
    Cristino J, Finek J, Jandova P, Kolek M, Pásztor B, Giannopoulou C, Qian Y, Brezina T, Lothgren M.
    J Med Econ; 2017 Aug 11; 20(8):799-812. PubMed ID: 28485692
    [Abstract] [Full Text] [Related]

  • 17. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
    Terpos E, Jamotte A, Christodoulopoulou A, Campioni M, Bhowmik D, Kennedy L, Willenbacher W.
    J Med Econ; 2019 Aug 11; 22(8):766-776. PubMed ID: 30969797
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Morgan GJ.
    Crit Rev Oncol Hematol; 2011 Feb 11; 77 Suppl 1():S24-30. PubMed ID: 21353177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.